tbuckley/cabot-search huggingface dataset:
Abstract 3751: Characterization of melanospheres from <i>BRAF</i>V600E mutated A2058 melanoma cell line.
Authors: Yi-Hua Liao, Jhu-Yun Deng, Min-Liang Kuo
Journal: Cancer Research (2013)

Abstract Increasing evidence suggests that there is a unique cell subpopulation in melanomas that possess stem cell-like activities and play important roles in tumor maintenance, metastasis, and chemo- or radio-resistance. It has been found that a subset of cells in human melanomas can form nonadherent melanospheres under serum-free stem cell medium. These sphere-forming cells have been demonstrated to have the capabilities of self-renewal and multi-differentiation similar to cancer stem cells. The goal of the study was to understand the features associated with tumorigenesis and melanoma progression in melanospheres compared to that in the adherent parental melanoma cells. We demonstrated that melanospheres had a higher tumorigenic ability than parental melanoma cells in that as few as 100 cells injected subcutaneously could form tumors. The tumorigenic ability was more enhanced in serially transplanted xenografts in severe combined immunodeficient mice as revealed by soft agar colony formation assay. Melanospheres showed chemo-resistance to cisplatin-induced cytotoxicity, which was also enhanced in cells derived from serially transplanted xenografts. Moreover, upregulation of markers of epithelial to mesenchymal transition (EMT) was found in melanospheres. The sphere-forming cells showed decreased levels of E-cadherin and significantly increased expression of the transcription factor SLUG/SNAI2. Taken together, these results suggested that melanosphere cultures represent a useful methodology to enrich and investigate melanoma cells with higher tumorigenic and metastatic potentials. Citation Format: Yi-Hua Liao, Jhu-Yun Deng, Min-Liang Kuo. Characterization of melanospheres from BRAFV600E mutated A2058 melanoma cell line. [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 3751. doi:10.1158/1538-7445.AM2013-3751
FRI0148 Family History in Turkish Ankylosing Spondylitis Patients Receiving Anti-TNF Therapy: Table 1.
Authors: U. Kalyoncu, P. Cetin, O. Karadag, I. Sari, L. Kilic, I. Ertenli, A. Akdogan, S. Kiraz, M. Birlik, F. Onen, S.A. Bilgen, N. Akkoc
Journal: Annals of the Rheumatic Diseases (2014)

<h3>Background</h3> About 7 to 36% of AS patients report family history for spondyloarthritis in their first and second degree relatives (1). It is of interest whether AS patients receiving anti-TNF therapy, who may be considered as having more active disease, report a high prevalence of family history, and/or a high prevalence of strong family history, which is defined as having two first degree relatives with AS, for the purpose of this study. <h3>Objectives</h3> The objective of this study was to assess the prevalence of family history among AS patients receiving biologic therapy, and to compare the patients with as strong family history with the rest of the patients who also reported family history. <h3>Methods</h3> A total of 683 patients (mean age 41±13, males % 68.5) with AS from two centers, who contribute to TURKBIO, a biological database in Turkey, and who had collected detailed information on family history were included in this retrospective analysis. The data in regard with the family history were extracted from patients9 hospital records without further validation, whereas the data for demographic characteristics, co-morbidities, smoking status, disease activity (BASDAI), functional status (BASFI), laboratory results (CRP, ESR) and all other assessment measures were obtained from the TURKBIO database. <h3>Results</h3> A positive family was noted in 200 (31.3%) patients, with 84 patients (males 69.2%) having AS in a first degree relative (13.1%) and 20 patients reporting a strong family history (3.1%) (Table 1). The patients had a mean age of 41±13 years and mean disease duration of 11±7 years. Except for a higher female predominance in patients with strong family history than in the other patients with family history (55% vs 74%, p=0.034), there were no differences in regard with the demographic data, BASDAI and BASFI (baseline and last visit), TNFi survival, TNFi switch ratio were all similar between the two groups. HLA-B27 results were available in 9 of the 20 patients with strong family history and 55% of them were positive for HLA-B27. <h3>Conclusions</h3> Prevalence of family history among AS patients on biologics seem to be similar to the figures reported in the literature. Disease characteristics among patients who have at least 2 relatives with AS do not seem to be different than the other patients having a less number or more distant relatives. It is of note convergence of HLA B27 with strong family history was not very high (55%), although it was tested in a very small number of patients. <h3>References</h3> Ann Rheum Dis 2004;63:535-543. <h3>Disclosure of Interest</h3> None declared <h3>DOI</h3> 10.1136/annrheumdis-2014-eular.5232
Abstract 4060: Enriching for rrare subpopulations of circulating microvesicles by the depletion of endothelial- and leukocyte-derived microvesicles
Authors: David B. Spetzler, Ta Deng, Teresa Tinder, Jeff Kimbrough, Phil Ellis, Daniel Holterman, Todd Maney, Christine D. Kuslich
Journal: Cancer Research (2011)

Abstract Endothelial- and leukocyte-derived circulating microvesicles (cMV) represent a majority of the cMV present in the blood. The purpose of this study was to determine if depletion of these more common cMV populations is possible, allowing for the enrichment and analysis of the remaining subpopulations of cMV. Circulating microvesicles were isolated from the blood plasma of breast cancer patients. Magnetic beads conjugated to antibodies specific for either CD31 or CD45 were used to deplete the isolated endothelial- and leukocyte-derived cMV. The remaining cMV population was characterized with a multiplexed immunoassay against a panel of 20 different antigens. In addition to the expected depletion of the biomarker used to remove the targeted cMV in the remaining cMV population, a concomitant depletion of associated biomarkers was observed. In the case of the cMV population in which CD31 had been used to remove endothelial-derived cMV, for instance, there was a significant concomitant depletion of DLL4, a highly associated endothelial marker. This was not the case with general epithelial microvesicle markers, such as CD9, which were still very much present in the cMV population remaining after depletion. These findings suggest a potential method for a more complete characterization of biomarker profiles associated with cMV derived from disease-associated cells and provide the foundation for a novel cMV-based strategy for disease detection through a noninvasive blood test. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 4060. doi:10.1158/1538-7445.AM2011-4060
THU0297 Severe Respiratory Infections in A Cohort of Patients Treated with Biologic Therapy for Rheumatic Diseases Including in A Protocol of Immunization
Authors: P. Rodriguez Cundin, V. Flor Morales, R. Blanco Alonso, F. Antolin Juarez, M. De la Cal Lopez, H. Rebollo Rodrigo, M.A. Gonzalez Gay, J. Mozota Ortiz
Journal: Annals of the Rheumatic Diseases (2014)

<h3>Background</h3> Severe Respiratory Infections (SRI) are relative frequent complications of biologic therapy. The vaccines can reduce these complications. <h3>Objectives</h3> To assess the SRI in a prospective cohort of patients with rheumatic diseases who were immunized following a protocol of immunization. <h3>Methods</h3> A protocol of immunization agreed beforehand between preventive and rheumatology service was established. In the first visit they initiated immunization for Pneumococcal, Haemophylus and Influenza vaccines. Influenza vaccine was only administered during the seasonal period (from October to April yearly in our hospital). At May 2013, pneumococcal conjugate was added to pneumococcal polysaccharide. Cohort study of 374 patients consecutively evaluated at the first visit for the vaccine consultation from 1 October 2011 to 31 September 2013. They were followed for a minimum period of one month and a maximum of two years. Data about episodes of SRI were collected from patients seen at emergency departments and hospitalisation. <h3>Results</h3> The mean age of the 374 patients was 53.1±15.4 (62.2% women/37.8% men). 8 of 374 patients refused to be vaccinated and 1 died before been vaccinated. The most frequent underlying diseases were Rheumatoid Arthritis (38.9%), Psoriatic arthritis (23.6%) and Ankylosing spondylitis (8,8%). A total of 225 (61.6%) patients were taking a biological drug (adalimumab 49,3%, etanercept 18,2%, infliximab 17,3%, tocilizumab 5,3%, Golimumab 5,%, Rituximab 3,5%, abatacept 0,4% and belimumab 0,4%) at the first visit. Combined therapy with other synthetic DMARDs was observed in 41.7% (mainly methotrexate). The following vaccines were prescribed: Influenza (n=365 patients), Haemophylus influenzae (n=360), Pneumococcal polysaccharide (n=322), Pneumococcal conjugate (n=178). 26 of 50 patients that had been immunized previously for pneumococcal polysaccharide, did not receive another dose. Throughout the follow-up, only 4 of 365 patients (1.1%) had a SRI. All of them required to be hospitalized, one with a tuberculous necrotizing granulomatous pneumonia, two with a bacterial pneumonia (E coli and other unidentified) and one with a lower respiratory tract infection without pulmonary condensation. <h3>Conclusions</h3> Our immunized cohort of patients with inflammatory rheumatic diseases had a low incidence of SRI. It seems that vaccination following a protocol of immunization may be useful. <h3>Disclosure of Interest</h3> : None declared <h3>DOI</h3> 10.1136/annrheumdis-2014-eular.4967
AB0249 Investigating the effect of etanercept on the peripheral B cell compartment in children with juvenile idiopathic arthritis
Authors: A. Meyer-Bahlburg, T. Quach, S. Gläsener, F. Dressler, N. Onken, F. Weller, H.-I. Huppertz, A. Thon
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Background</h3> Both B cells and TNF have been shown to play an important role in the pathogenesis of rheumatoid arthritis and juvenile idiopathic arthritis (JIA). However, it remains unclear whether these two important players and the therapies that target them are mechanistically linked. In particular, the impact of TNF-α inhibition on the B cell compartment in children with juvenile idiopathic arthritis has not been investigated so far. In adult patients with rheumatoid arthritis, two recent studies demonstrate a decrease in memory B cells as a result of anti-TNF treatment using Etanercept<sup>1</sup> or Infliximab<sup>2</sup>, respectively, in patients with rheumatoid arthritis. However, so far no studies have been performed in patients with JIA in this respect. Changes within the composition of the B cell subpopulations could be a direct effect of Etanercept. Alternatively, it might be caused indirectly through alterations in T cells or BAFF signaling. <h3>Objectives</h3> This study was designed to analyze impact of Etanercept therapy on the composition of both the B and T cell compartment and the BAFF system in patients with JIA. <h3>Methods</h3> B and T cell subpopulations in the peripheral blood from patients with JIA were investigated by multicolor flow cytometry. Serum BAFF and APRIL levels were determined by ELISA. In addition, standard laboratory parameters including C-reactive protein, whole blood cell count,blood sedimentation rate and immunoglobulin levels were collected. <h3>Results</h3> To date, more than 150 patients have been included into the study. Patients are grouped based on current treatment with Etanerpcet, Methotrexate or NSAID. First data demonstrate that treatment with MTX has an effect on the composition of the B cell compartment and leads to slighty decreased total immonoglobulin levels. In contrast, no obvious decrease in memory B cells after TNF inhibition as described in adult patients<sup>1,2</sup> with arthritis could be observed in our cohort of JIA patients. <h3>Conclusions</h3> Anti-rheumatic therapy has an impact on the B cell compartment in patients with JIA. <h3>References</h3> Anolik, JH, et al: Cutting edge: anti-tumor necrosis factor therapy in rheumatoid arthritis inhibits memory B lymphocytes via effects on lymphoid germinal centers and follicular dendritic cell networks. J Immunol 2008;180:688. Souto-Carneiro, MM, et al: Alterations in peripheral blood memory B cells in patients with active rheumatoid arthritis are dependent on the action of tumour necrosis factor. Arthritis Res Ther 2009;11:R84. <h3>Disclosure of Interest</h3> None Declared
Abstract 2250: Aberrant leukocyte infiltration as a trigger for tumor metastasis
Authors: Yi-Hsuan Hsiao, Yan-Gao Man
Journal: Cancer Research (2010)

Abstract Our previous studies have led to a novel hypothesis that aberrant leukocyte infiltration is a trigger for tumor invasion. Our hypothesis and supporting data have been published in multiple peer-reviewed journals. Our current studies attempted to further expand our previous observations, and to test a novel hypothesis that aberrant leukocyte infiltration may also represent a trigger for tumor metastasis. Tissue sections from human breast, prostate, cervical, and lung tumors were analyzed with multidisciplinary approaches with a panel of tumor metastasis-related biomarkers. Our study revealed that pre-invasive tumors surrounded by or immediately adjacent to leukocyte aggregates displayed a number of unique features: [1] significantly reduced expression of cell surface adhesion molecules, [2] significantly elevated blood vessels and lymphatic ducts at the intersection between the tumor core and leukocyte aggregates, [3] the presence of isolated individual tumor cells or cell clusters within the leukocyte aggregates, [4] physical attachment or fusion of tumor cell membrane and condensed chromosomes of mitotic tumor cells with leukocytes, and [5] the presence of co-joined tumor cells and leukocytes within vascular structures or lymphatic ducts. Together, our findings suggest that leukocyte infiltration may trigger tumor metastasis through three correlated mechanisms: (1) to physically disrupt the inter-cellular junctions and cell surface adhesion molecules, [2] to interfere with the mitotic process or physically drag tumor cells to different sites during their migration, and [3] to stimulate growth of vascular structures that facilitate tumor metastasis. (Supported in part by grants DAMD17-01-1-0129, DAMD17-01-1-0130, PC051308 from Congressionally Directed Medical Research Programs, grant BCTR0706983 from The Susan G. Komen Breast Cancer Foundation, and grant 2008-02 from The US Military Cancer Institute and Henry M. Jackson Foundation to Dr. Yan-gao Man, and by grant 2006CB910505 from The Ministry of Chinese Science and Technology Department to Drs. Xichen Zhang and Yan-gao Man). Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 2250.
A2.09 Longitudinal EBV antibody profiling in sle patients reveals patients with lupus nephritis
Authors: HM van Dongen, N Masoumi, M Tsang-A-Sjoe, JM Middeldorp, AE Voskuyl, DM Pegtel
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background and objectives</h3> The cause of systemic lupus erythematosus (SLE), a severe autoimmune disease, remains unclear. Genetic predisposition cannot be the only explanation for the emergence of SLE and environmental factors could contribute to the complex aetiology of this disease. Epstein-Barr virus (EBV) infection has been implied as a possible factor in early SLE pathogenesis. This study aimed to obtain anti-EBV antibody characteristics in a longitudinal SLE serum cohort, to find correlations between anti-EBV reactivity and disease activity, including lupus nephritis (LN), and to show their clinical utility as a diagnostic marker in SLE. <h3>Materials and methods</h3> Blood samples were taken yearly from patients included in the Amsterdam SLE cohort (start 2007). Longitudinal characteristics of the anti-EBV antibody profile in SLE patient serum (n = 30), were tested blind with the immunoblot technique, using 3 mm nitrocellulose strips produced with SDS page and electrophoretic transfer of EBV lytic phase antigens. EBV antigens were obtained from nuclear extract of HH514.c16 cells induced with TPA/sodium butyrate for expression of EBV lytic phase. Patterns were compared to clinical characteristics, including SLEDAI (SLE disease activity index) and occurrence of lupus nephritis. <h3>Results</h3> We found that immune-reactivity against EBV antigens in the serum of SLE is highly perturbed when compared to healthy individuals. Virtually all patients had positive reactivity of IgG antibodies against latent (EBNA1) and lytic (EAd, Zebra, VCA) EBV associated antigens. The patterns of reactivity changed overtime and are possibly related to disease activity (SLEDAI). Strikingly, SLE patients that develop lupus nephritis seem to have an altered serum reactivity for currently unknown antigens, up to two years before clinical diagnosis. <h3>Conclusions</h3> Our results strongly suggest associations of EBV antibody reactivity in SLE patients. This suggests aberrant EBV control in all SLE patients but particular in those with renal involvement. The results warrant larger studies measuring EBV serum reactivity as a possible prognostic biomarker for renal involvement in SLE and response to treatment.
A fish bone perforation of the esophagus
Authors: Akira Hokama, Kayoko Uechi, Eriko Takeshima, Chiharu Kobashigawa, Atsushi Iraha, Tetsu Kinjo, Kazuto Kishimoto, Fukunori Kinjo, Jiro Fujita
Journal: Endoscopy (2014)

A 73-year-old man presented with odynophagia and retrosternal pain of 3 days' duration following a fish meal. Physical examination disclosed normal vital signs and a temperature of 37.2 °C. Laboratory studies showed elevated white blood cells of 13 900/μL and C-reactive protein of 14.8 mg/dL. A computed tomography (CT) of the chest revealed a suspicious fish bone that measured 3 cm in length and had perforated through the esophageal wall ([Fig. 1] and [Fig. 2]). Three-dimensional CT showed the bone (blue matter) penetrating close to the left common carotid artery ([Fig. 3]). Subsequent upper endoscopy revealed only a small submucosal nodule, which was located at 19 cm from the incisors, not an impacted fish bone in the upper esophagus ([Fig. 4]). A tiny white linear scar (arrow) was observed on its top, suggesting the site of perforation ([Fig. 5]). Surgical exploration was performed via a lateral neck incision, and the fish bone was successfully retrieved. The postoperative course was uneventful.
AB0653 Auditory evoked potentials in diagnosis of fibromyalgia
Authors: D. Al-Zifzaf, N. S. Kamel, N. Kamal, A. El-Ganzoury, A. N. Omar, A. A.-L. Abdel-Kader
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Background</h3> At present, the lack of an objective laboratory test or an imaging technique hampers fibromyalgia (FM) recognition and hence treatment (<b>Lerma et al., 2012</b>). The most agonizing symptom in FM is pain and the most accepted theory in explaining this pain is the central sensitization theory (<b>Bennett et al., 2012</b>). Hypervigilance is a component of central sensitization pain which was reported in FM patients (<b>González et al., 2010</b>). Auditory evoked Potentials (AEPs) are brain waves generated upon stimulation with sounds. They reflect the ability of the brain to discriminate, classify, and memorize the significance of exogenous stimuli (<b>Giaquinto, 2004</b>). <h3>Objectives</h3> Was to assess the role of AEPs as an objective diagnostic tool for hypervigilance and cognitive function of FM. <h3>Methods</h3> This study was conducted on thirty FM female patients, fulfilling the 1990 ACR criteria and a group age matched female controls. All subjects undertook thorough clinical examination, psychiatric and functional assessment (Sleep score, Fibromyalgia impact questionnaire and hospital anxiety and depression scale) as well as measurement of AEPs elicited by tones of increasing intensity (60, 70, 80, and 90 dB) known as late cortical responses and cognitive auditory potentials known as (Event Related Potentials) ERPs (P300). <h3>Results</h3> Patients had significantly shorter latencies than controls of N1 at (60 and 70dB) (p&lt;0.001) and they also showed significantly shorter P2 latencies at all the studied intensities (p&lt;0.001). Patients had increased P300 latency and decreased P300 amplitude compared to controls (p&lt;0.05, p&lt;0.001 respectively). The diagnostic performance of different AEPs in FM patients as regard sensitivity and specificity between patients and controls varied. The best performance was by the measurement of N160dB with the cutoff point values at 102 msec, specificity was 80% and sensitivity 90%. <h3>Conclusions</h3> This study emphasizes the diagnostic value of AEPs for hypervigilance and cognitive ability in FM. This report applies to both components of AEPs (late cortical and cognitive) which proved to be relatively sensitive and specific tests for FM. <h3>References</h3> Bennett R, Russell IJ, Choy E, et al., 2012: Evaluation of patient-rated stiffness associated with fibromyalgia. Clin Ther. Apr;34(4):824-37. Giaquinto S (2004): Evoked potentials in rehabilitation. Funct Neurol. 19 (4):219-25. González JL, Mercado F, Barjola P, et al.,(2010): Generalized hypervigilance in fibromyalgia patients: an experimental analysis with the emotional Stroop paradigm. J Psychosom Res.;69(3). Lerma C, Martinez A, Ruiz N, et al., 2011: Nocturnal heart rate variability parameters as potential fibromyalgia biomarker: correlation with symptoms severity Arthritis Res Ther.;13(6):R185. <h3>Disclosure of Interest</h3> None Declared